Infections in HIV infection

Genitai herpes Treatment or suppression of recurrent episodes of genital herpes. Herpes simpiex Treatment of recurrent mucocutaneous herpes simplex infections in HIV-infected patients. [Pg.1758]

Recurrent orolabial and genital herpes simplex infection in HIV-infected patients... [Pg.1760]

Newer agents of this class are famciclovir and cidofovir. Famciclovir is a prodrug of penciclovir with improved oral bioavailability. It is labelled for the suppression of recurrent episodes of genital herpes in immunocompetent adults and for the treatment of recurrent mucocutaneous herpes simplex infections in HIV-infected patients. [Pg.420]

The initial signs of disease may become apparent at any time during the evolution of HIV infection. In HIV-infected patients TBC may be pulmonary or extra-pulmonary. Pulmonary TBC is still the most common form of TBC. The presentation depends on the degree of immunosuppression. In advanced HIV... [Pg.564]

Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Recommendations of the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the HIV Medicine Association of the Infectious Diseases Society of America (HIVMA/IDSA). AIDSinfo June 18, 2008. http //Al DSi nfo. n i h. gov... [Pg.1115]

A multicenter, randomized, placebo-controlled study showed oral valacyclovir (500 mg, twice daily) effective for the suppression of recurrent genital HSV infections in HIV-infected participants (Dejesus et al.). [Pg.199]

Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, Crooks RJ, Acebes LO, Aiuti F, Akil B, Anderson J, Melville RL, Ballesteros Martin J, Berry A, Weiner M, Black F, Anderson PL, Bockman W, Borelli S, Bradbeer CS, Braffman M, Brandon W, Clark R, Wisniewski T, Bruun JN, Burdge D, Caputo RM, Chateauvert M, LaLonde R, Chiodo F, et al. International Valaciclovir HSV Study Group. Valaciclovir versus aciclovir for Herpes simplex virus infection in HIV-infected individuals two randomized trials. Int J STD AIDS 2002 13(1) 12-21. [Pg.31]

In a study of oral famciclovir versus oral aciclovir, designed to demonstrate equivalence of efficacy of the two drugs in the treatment of mucocutaneous Herpes simplex infection in HIV-infected individuals, there was no difference in the incidence or nature of adverse effects in the two groups (1). None of the withdrawals from the trial was considered by the investigator to be related to the study medication. [Pg.1326]

Torriani EJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, et al, APRICOT Study Group. Pegin-terferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004 351 438-50. [Pg.1846]

Until recently, a rapid presumptive identification of C. albicans could be made by incubation of the organism in serum formation of a germ tube (the beginning of hyphae, which arise as perpendicular extensions from the yeast cell, with no constriction at their point of origin) within 1 to 2 hours offered a positive identification of C. albicans. Unformnately, C. dubliniensis, a new species of Candida that was identified recently as an important cause of mucosal colonization and infection in HIV-infected individuals, also can produce a germ mbe. A negative germ tube test does not rule out the possibility of C. albicans, but further biochemical tests must be performed to differentiate between other non-albicans species. ... [Pg.2178]

Rifabutin is effective for the prevention of MAC infection in HIV-infected individuals. At a dose of 3(X) mg per day, rifabutin decreased the frequency of MAC bacteremia (2%). However, azithromycin or clarithromycin are more effective and less likely to interact with highly active antiretroviral therapy (HAART) drugs. Rifabutin also is commonly substituted for rifampin in the treatment of tuberculosis in HIV-infected patients, as it has a less profound CYP-dependent interaction with indinavir and nelfinavir. Rifabutin also is used in combination with clarithromycin and ethambutol for the therapy of MAC disease. [Pg.620]

The lung is a frequent site of opportunistic infection in HIV-infected individuals, and pulmonary infections are a major cause of morbidity and mortality (108,109). [Pg.179]

HBV infection in HIV-infected persons is more likely to lead to chronic HBV infection. HIV infection also can impair the response to hepatitis B vaccine. Therefore, HIV-infected persons who are vaccinated should be tested for hepatitis B surface antibody 1-2 months after the third vaccine dose. Revaccination with three more doses should be considered for those who do not respond initially to vaccination. Those who do not respond to additional doses should be advised that they might remain susceptible to HBV infection. [Pg.416]

Kaplan JE, Benson C, Holmes KK et al (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adult and adolescent. MMVVR Recomm Rep 58(RR04) 1-198... [Pg.88]

Stroud L, Srivastava P, Culver D, Bisno A, Rimland D, Simberkoff M, et al. Nosocomial infections in HIV-infected patients preliminary results from a multicenter surveillance system (1989-1995). Infect Control Hosp Epidemiol 1997 18 479-485. [Pg.86]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...